News

Filter

Current filters:

Anti-viralsUSA

1 to 9 of 86 results

Janssen's Prezcobix approved for HIV in the USA

Janssen's Prezcobix approved for HIV in the USA

30-01-2015

The US Food and Drug Administration has approved Prezcobix (darunavir 800mg/cobicistat 150mg) tablets,…

Anti-viralsJanssenPharmaceuticalPrezcobixRegulationUSA

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

22-01-2015

In an open letter to pharmacy professions, US pharma giant Merck & Co has advised that it is voluntarily…

Anti-viralsMarkets & MarketingMerck & CoPharmaceuticalUSAVictrelis

Court orders SIGA to pay $195,000 in case brought by PharmAthene for Tecovirimat

Court orders SIGA to pay $195,000 in case brought by PharmAthene for Tecovirimat

16-01-2015

The Delaware Court of Chancery has entered its Final Order and Judgment in the case brought by US pharma…

Anti-viralsLegalPharmaceuticalPharmAtheneSIGA TechnologiesTecovirimatUSA

Tekmira to merge with OnCore, to create major hep B company

Tekmira to merge with OnCore, to create major hep B company

14-01-2015

Shares of Tekmira Pharmaceuticals leapt as much as 50% after it announced a merger with privately-held…

Anti-viralsBiotechnologyOnCore BioPharmaOnCore BioPharmaTekmira PharmaceuticalsUSA

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

Merck & Co updates on plans to accelerate new drug submissions and future growth

Merck & Co updates on plans to accelerate new drug submissions and future growth

13-01-2015

US pharma giant Merck & Co has reported on the ongoing execution of its multi-year, strategic initiative…

Anti-viralsgrazoprevir/elbasvirKeytrudaMerck & CoOncologyPharmaceuticalRegulationResearchUSA

US insurance firm Anthem chooses Gilead’s Harvoni as primary HCV drug

US insurance firm Anthem chooses Gilead’s Harvoni as primary HCV drug

12-01-2015

US biotech major Gilead Sciences has signed an agreement with US health insurance firm Anthem to provide…

Anti-viralsGileadHarvoniPharmaceuticalPricingUSA

1 to 9 of 86 results

COMPANY SPOTLIGHT

Menarini

Back to top